| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Panax | 57 | 2017 | 170 | 14.140 |
Why?
|
| Plant Extracts | 64 | 2017 | 244 | 12.680 |
Why?
|
| Phytotherapy | 42 | 2016 | 133 | 10.320 |
Why?
|
| Ginsenosides | 39 | 2016 | 123 | 9.430 |
Why?
|
| Antineoplastic Agents, Phytogenic | 25 | 2016 | 276 | 7.170 |
Why?
|
| Naltrexone | 24 | 2013 | 135 | 4.440 |
Why?
|
| Narcotic Antagonists | 24 | 2013 | 154 | 4.420 |
Why?
|
| Colorectal Neoplasms | 30 | 2014 | 938 | 4.100 |
Why?
|
| Drugs, Chinese Herbal | 19 | 2015 | 67 | 3.670 |
Why?
|
| Flavonoids | 12 | 2015 | 85 | 3.090 |
Why?
|
| Chromatography, High Pressure Liquid | 23 | 2016 | 315 | 3.070 |
Why?
|
| Panax notoginseng | 7 | 2016 | 23 | 2.920 |
Why?
|
| Apoptosis | 34 | 2016 | 1683 | 2.920 |
Why?
|
| Cell Proliferation | 27 | 2015 | 1579 | 2.840 |
Why?
|
| Oplopanax | 7 | 2014 | 29 | 2.790 |
Why?
|
| Plant Roots | 28 | 2017 | 106 | 2.660 |
Why?
|
| Antioxidants | 13 | 2014 | 223 | 2.650 |
Why?
|
| Saponins | 13 | 2016 | 41 | 2.600 |
Why?
|
| Sapogenins | 7 | 2016 | 24 | 2.520 |
Why?
|
| Colonic Neoplasms | 8 | 2017 | 557 | 2.370 |
Why?
|
| Fruit | 13 | 2011 | 75 | 2.270 |
Why?
|
| Cell Cycle | 19 | 2015 | 502 | 2.120 |
Why?
|
| Fluorouracil | 8 | 2015 | 556 | 2.120 |
Why?
|
| Plants, Medicinal | 12 | 2014 | 42 | 2.030 |
Why?
|
| Hypoglycemic Agents | 12 | 2014 | 378 | 1.990 |
Why?
|
| Scutellaria baicalensis | 9 | 2015 | 26 | 1.870 |
Why?
|
| Analgesics, Opioid | 13 | 2013 | 413 | 1.830 |
Why?
|
| Animals | 92 | 2017 | 26590 | 1.650 |
Why?
|
| Flavanones | 8 | 2015 | 35 | 1.600 |
Why?
|
| Brain Stem | 11 | 2004 | 165 | 1.590 |
Why?
|
| Pica | 6 | 2007 | 14 | 1.570 |
Why?
|
| Mass Spectrometry | 4 | 2016 | 189 | 1.560 |
Why?
|
| Morphine | 11 | 2004 | 130 | 1.550 |
Why?
|
| Vitis | 7 | 2011 | 19 | 1.450 |
Why?
|
| Blood Glucose | 12 | 2014 | 873 | 1.440 |
Why?
|
| Myocytes, Cardiac | 8 | 2011 | 275 | 1.440 |
Why?
|
| Cell Line, Tumor | 29 | 2014 | 2426 | 1.410 |
Why?
|
| Constipation | 7 | 2013 | 63 | 1.400 |
Why?
|
| Anticarcinogenic Agents | 5 | 2013 | 70 | 1.380 |
Why?
|
| Solitary Nucleus | 11 | 2004 | 21 | 1.380 |
Why?
|
| Colitis | 4 | 2017 | 239 | 1.320 |
Why?
|
| Oxidative Stress | 9 | 2008 | 448 | 1.310 |
Why?
|
| Stomach | 9 | 2004 | 108 | 1.300 |
Why?
|
| Leptin | 6 | 2009 | 105 | 1.290 |
Why?
|
| HCT116 Cells | 15 | 2015 | 151 | 1.280 |
Why?
|
| Drug Synergism | 12 | 2015 | 303 | 1.260 |
Why?
|
| Quaternary Ammonium Compounds | 23 | 2013 | 79 | 1.220 |
Why?
|
| Plant Preparations | 3 | 2016 | 19 | 1.210 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2017 | 456 | 1.180 |
Why?
|
| Biological Products | 4 | 2014 | 143 | 1.150 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2015 | 236 | 1.140 |
Why?
|
| Antineoplastic Agents | 13 | 2014 | 2360 | 1.110 |
Why?
|
| Neurons | 10 | 2016 | 1547 | 1.070 |
Why?
|
| Gastrointestinal Transit | 9 | 2005 | 19 | 1.070 |
Why?
|
| Carcinogenesis | 2 | 2017 | 195 | 1.020 |
Why?
|
| Smilax | 2 | 2015 | 5 | 1.020 |
Why?
|
| Mice | 32 | 2017 | 11356 | 1.020 |
Why?
|
| Hyperuricemia | 2 | 2015 | 27 | 0.990 |
Why?
|
| Obesity | 8 | 2011 | 964 | 0.980 |
Why?
|
| Cisplatin | 7 | 2006 | 612 | 0.980 |
Why?
|
| Dose-Response Relationship, Drug | 21 | 2013 | 1961 | 0.970 |
Why?
|
| Neoplasms | 7 | 2016 | 2898 | 0.950 |
Why?
|
| Humans | 98 | 2016 | 86656 | 0.950 |
Why?
|
| Chromatography, Liquid | 2 | 2016 | 105 | 0.930 |
Why?
|
| Vomiting | 7 | 2012 | 193 | 0.910 |
Why?
|
| Proanthocyanidins | 5 | 2011 | 12 | 0.880 |
Why?
|
| Disease Models, Animal | 18 | 2016 | 2231 | 0.860 |
Why?
|
| Rats | 25 | 2012 | 3992 | 0.850 |
Why?
|
| Narcotics | 5 | 2006 | 69 | 0.850 |
Why?
|
| Drug Contamination | 2 | 2014 | 12 | 0.840 |
Why?
|
| Reishi | 3 | 2007 | 7 | 0.840 |
Why?
|
| Purkinje Fibers | 5 | 2001 | 27 | 0.820 |
Why?
|
| Reactive Oxygen Species | 13 | 2014 | 480 | 0.810 |
Why?
|
| Nausea | 7 | 2012 | 175 | 0.770 |
Why?
|
| Rats, Sprague-Dawley | 17 | 2014 | 1221 | 0.770 |
Why?
|
| Gastrointestinal Motility | 4 | 2006 | 25 | 0.750 |
Why?
|
| Pain | 5 | 2004 | 391 | 0.750 |
Why?
|
| Body Weight | 10 | 2013 | 458 | 0.740 |
Why?
|
| Free Radical Scavengers | 5 | 2013 | 59 | 0.720 |
Why?
|
| Breast Neoplasms | 6 | 2013 | 2903 | 0.710 |
Why?
|
| Injections, Intraperitoneal | 11 | 2011 | 102 | 0.710 |
Why?
|
| Oxidants | 6 | 2007 | 86 | 0.700 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2011 | 1375 | 0.690 |
Why?
|
| Male | 52 | 2017 | 40983 | 0.680 |
Why?
|
| Mice, Obese | 10 | 2011 | 44 | 0.680 |
Why?
|
| Medicine, Chinese Traditional | 3 | 2012 | 9 | 0.660 |
Why?
|
| Reperfusion Injury | 2 | 2011 | 131 | 0.630 |
Why?
|
| Caspases | 5 | 2013 | 155 | 0.610 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2009 | 191 | 0.610 |
Why?
|
| Cell Survival | 12 | 2010 | 969 | 0.610 |
Why?
|
| Antiemetics | 5 | 2007 | 98 | 0.600 |
Why?
|
| Diynes | 2 | 2013 | 7 | 0.570 |
Why?
|
| Fatty Alcohols | 2 | 2013 | 10 | 0.570 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 104 | 0.570 |
Why?
|
| Herbal Medicine | 3 | 2012 | 8 | 0.560 |
Why?
|
| Dietary Supplements | 4 | 2005 | 128 | 0.560 |
Why?
|
| Phenols | 2 | 2006 | 40 | 0.560 |
Why?
|
| Azoxymethane | 4 | 2017 | 82 | 0.550 |
Why?
|
| Hot Temperature | 4 | 2013 | 206 | 0.540 |
Why?
|
| Hydrogen Peroxide | 6 | 2008 | 158 | 0.540 |
Why?
|
| Crocus | 2 | 2013 | 3 | 0.540 |
Why?
|
| Catechin | 2 | 2012 | 19 | 0.530 |
Why?
|
| Mice, Nude | 6 | 2015 | 790 | 0.520 |
Why?
|
| Dextran Sulfate | 4 | 2017 | 68 | 0.520 |
Why?
|
| Plant Leaves | 5 | 2006 | 72 | 0.520 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 25 | 0.510 |
Why?
|
| Allopurinol | 1 | 2015 | 80 | 0.500 |
Why?
|
| Glycosides | 1 | 2014 | 20 | 0.500 |
Why?
|
| Animals, Newborn | 9 | 2009 | 510 | 0.500 |
Why?
|
| Uricosuric Agents | 1 | 2014 | 11 | 0.500 |
Why?
|
| Cell Death | 3 | 2013 | 256 | 0.500 |
Why?
|
| Complementary Therapies | 3 | 2010 | 54 | 0.500 |
Why?
|
| Daphne | 1 | 2014 | 9 | 0.490 |
Why?
|
| Vagus Nerve | 4 | 2004 | 45 | 0.490 |
Why?
|
| Chick Embryo | 9 | 2009 | 229 | 0.480 |
Why?
|
| Glucose Tolerance Test | 8 | 2014 | 228 | 0.480 |
Why?
|
| Arthritis, Experimental | 1 | 2014 | 24 | 0.480 |
Why?
|
| Membrane Potential, Mitochondrial | 3 | 2013 | 29 | 0.480 |
Why?
|
| Diabetes Mellitus | 5 | 2005 | 806 | 0.470 |
Why?
|
| NF-kappa B | 3 | 2014 | 445 | 0.460 |
Why?
|
| Genistein | 1 | 2013 | 16 | 0.460 |
Why?
|
| Seeds | 5 | 2009 | 49 | 0.460 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2013 | 381 | 0.460 |
Why?
|
| Steroids | 1 | 2014 | 177 | 0.450 |
Why?
|
| Structure-Activity Relationship | 6 | 2016 | 408 | 0.450 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2013 | 52 | 0.450 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2015 | 458 | 0.440 |
Why?
|
| Bufanolides | 3 | 2001 | 5 | 0.430 |
Why?
|
| Rats, Wistar | 7 | 2007 | 297 | 0.430 |
Why?
|
| Mitochondria | 2 | 2013 | 535 | 0.430 |
Why?
|
| Plant Stems | 2 | 2009 | 9 | 0.420 |
Why?
|
| Bile | 1 | 2012 | 57 | 0.420 |
Why?
|
| Herb-Drug Interactions | 1 | 2011 | 4 | 0.420 |
Why?
|
| Chemoprevention | 4 | 2013 | 91 | 0.420 |
Why?
|
| Administration, Oral | 9 | 2011 | 684 | 0.410 |
Why?
|
| Cardiotonic Agents | 3 | 2001 | 88 | 0.410 |
Why?
|
| Cold Temperature | 5 | 2004 | 157 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2015 | 2438 | 0.400 |
Why?
|
| Mice, Inbred C57BL | 10 | 2012 | 3095 | 0.400 |
Why?
|
| Molecular Structure | 5 | 2015 | 287 | 0.400 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 339 | 0.400 |
Why?
|
| Camptothecin | 1 | 2012 | 189 | 0.390 |
Why?
|
| Methadone | 3 | 2000 | 36 | 0.390 |
Why?
|
| Publishing | 1 | 2012 | 90 | 0.380 |
Why?
|
| Flow Cytometry | 5 | 2010 | 679 | 0.380 |
Why?
|
| Cyclin A | 4 | 2013 | 28 | 0.370 |
Why?
|
| Antimycin A | 3 | 2006 | 13 | 0.360 |
Why?
|
| Intra-Abdominal Fat | 1 | 2009 | 29 | 0.360 |
Why?
|
| Biological Availability | 3 | 2016 | 92 | 0.360 |
Why?
|
| Drug Interactions | 7 | 2012 | 248 | 0.350 |
Why?
|
| Gene Expression Profiling | 3 | 2014 | 1384 | 0.350 |
Why?
|
| Araliaceae | 1 | 2009 | 2 | 0.350 |
Why?
|
| Adiposity | 1 | 2009 | 70 | 0.350 |
Why?
|
| Coronary Disease | 1 | 2011 | 261 | 0.350 |
Why?
|
| Signal Transduction | 4 | 2014 | 3243 | 0.340 |
Why?
|
| Cells, Cultured | 9 | 2007 | 2819 | 0.340 |
Why?
|
| Double-Blind Method | 10 | 2014 | 1824 | 0.340 |
Why?
|
| Female | 28 | 2014 | 44546 | 0.330 |
Why?
|
| Gastric Emptying | 3 | 2008 | 23 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 1376 | 0.330 |
Why?
|
| Muscimol | 4 | 2004 | 18 | 0.330 |
Why?
|
| Weight Gain | 1 | 2009 | 123 | 0.330 |
Why?
|
| Eating | 3 | 2009 | 166 | 0.330 |
Why?
|
| GABA Antagonists | 4 | 2004 | 25 | 0.330 |
Why?
|
| Baclofen | 3 | 2004 | 15 | 0.320 |
Why?
|
| Weight Loss | 1 | 2009 | 229 | 0.310 |
Why?
|
| HIV Protease Inhibitors | 1 | 2007 | 21 | 0.310 |
Why?
|
| Ritonavir | 1 | 2007 | 12 | 0.310 |
Why?
|
| Heart | 2 | 2002 | 539 | 0.310 |
Why?
|
| Cell Division | 2 | 2006 | 696 | 0.310 |
Why?
|
| Carotenoids | 1 | 2007 | 14 | 0.310 |
Why?
|
| Intestinal Mucosa | 3 | 2014 | 797 | 0.300 |
Why?
|
| Central Nervous System Agents | 3 | 2001 | 15 | 0.300 |
Why?
|
| Valerian | 2 | 2004 | 3 | 0.290 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2001 | 58 | 0.290 |
Why?
|
| Receptors, Opioid, mu | 2 | 2013 | 45 | 0.280 |
Why?
|
| Cholesterol | 2 | 2006 | 356 | 0.280 |
Why?
|
| Murraya | 1 | 2006 | 2 | 0.280 |
Why?
|
| Kava | 2 | 2002 | 3 | 0.280 |
Why?
|
| Flowers | 3 | 2014 | 36 | 0.280 |
Why?
|
| Electrophysiology | 6 | 2004 | 401 | 0.270 |
Why?
|
| Area Under Curve | 5 | 2005 | 334 | 0.270 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2013 | 78 | 0.270 |
Why?
|
| Adult | 21 | 2016 | 25656 | 0.270 |
Why?
|
| Kaolin | 4 | 2007 | 9 | 0.270 |
Why?
|
| Nitric Oxide | 4 | 2014 | 278 | 0.260 |
Why?
|
| Platelet Activation | 1 | 2005 | 13 | 0.260 |
Why?
|
| Angelica | 1 | 2004 | 2 | 0.260 |
Why?
|
| Organic Anion Transport Protein 1 | 2 | 2015 | 4 | 0.260 |
Why?
|
| Glucose Transport Proteins, Facilitative | 2 | 2015 | 5 | 0.260 |
Why?
|
| Corydalis | 1 | 2004 | 4 | 0.260 |
Why?
|
| Strophanthidin | 2 | 2001 | 3 | 0.260 |
Why?
|
| Polyphenols | 3 | 2012 | 13 | 0.250 |
Why?
|
| Organic Anion Transporters | 2 | 2015 | 27 | 0.250 |
Why?
|
| Cell Cycle Checkpoints | 3 | 2013 | 63 | 0.250 |
Why?
|
| Cholecystokinin | 2 | 2002 | 15 | 0.250 |
Why?
|
| Blood Coagulation | 1 | 2005 | 91 | 0.250 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 146 | 0.240 |
Why?
|
| Indenes | 1 | 2004 | 9 | 0.240 |
Why?
|
| Digestive System | 2 | 2001 | 42 | 0.240 |
Why?
|
| Receptors, GABA | 1 | 2004 | 10 | 0.240 |
Why?
|
| Sesquiterpenes | 1 | 2004 | 13 | 0.240 |
Why?
|
| Ephedra sinica | 1 | 2004 | 1 | 0.240 |
Why?
|
| Scutellaria | 1 | 2004 | 3 | 0.240 |
Why?
|
| Mitochondria, Heart | 2 | 2002 | 50 | 0.240 |
Why?
|
| Uric Acid | 2 | 2015 | 139 | 0.240 |
Why?
|
| Insulin-Secreting Cells | 1 | 2008 | 397 | 0.240 |
Why?
|
| Warfarin | 1 | 2004 | 103 | 0.230 |
Why?
|
| Gymnema | 1 | 2003 | 1 | 0.230 |
Why?
|
| Colon | 4 | 2013 | 496 | 0.230 |
Why?
|
| Heterografts | 2 | 2014 | 98 | 0.230 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 2 | 2013 | 11 | 0.230 |
Why?
|
| Myocardium | 3 | 2002 | 529 | 0.230 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2009 | 1075 | 0.230 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2004 | 67 | 0.230 |
Why?
|
| Electroacupuncture | 1 | 2003 | 1 | 0.230 |
Why?
|
| Pyrones | 1 | 2002 | 8 | 0.220 |
Why?
|
| GABA Agents | 1 | 2002 | 8 | 0.220 |
Why?
|
| Risk | 3 | 2013 | 674 | 0.220 |
Why?
|
| Nucleus Accumbens | 1 | 2004 | 113 | 0.220 |
Why?
|
| Lactones | 1 | 2002 | 28 | 0.220 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2014 | 83 | 0.220 |
Why?
|
| Acupressure | 1 | 2002 | 1 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 1197 | 0.220 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2001 | 187 | 0.220 |
Why?
|
| Pain Threshold | 1 | 2003 | 58 | 0.220 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2002 | 12 | 0.220 |
Why?
|
| Cell Hypoxia | 2 | 2002 | 164 | 0.220 |
Why?
|
| Digestive System Physiological Phenomena | 1 | 2002 | 4 | 0.220 |
Why?
|
| Galanin | 1 | 2002 | 6 | 0.220 |
Why?
|
| China | 2 | 2014 | 228 | 0.220 |
Why?
|
| Receptors, Opioid | 2 | 2006 | 24 | 0.220 |
Why?
|
| Gene Expression | 3 | 2013 | 1284 | 0.210 |
Why?
|
| Breath Tests | 5 | 2002 | 55 | 0.210 |
Why?
|
| Anti-Obesity Agents | 1 | 2002 | 14 | 0.210 |
Why?
|
| Peripheral Nervous System | 1 | 2002 | 21 | 0.210 |
Why?
|
| Cardiac Glycosides | 1 | 2001 | 5 | 0.210 |
Why?
|
| Digoxin | 1 | 2001 | 21 | 0.200 |
Why?
|
| Pain Management | 1 | 2003 | 127 | 0.200 |
Why?
|
| Electric Stimulation | 5 | 2004 | 347 | 0.200 |
Why?
|
| G1 Phase | 2 | 2012 | 63 | 0.200 |
Why?
|
| In Vitro Techniques | 5 | 2003 | 989 | 0.200 |
Why?
|
| Lamiaceae | 1 | 2001 | 2 | 0.200 |
Why?
|
| Sodium Channel Blockers | 1 | 2001 | 27 | 0.200 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 1998 | 46 | 0.200 |
Why?
|
| Acetaminophen | 2 | 1998 | 54 | 0.200 |
Why?
|
| Anticoagulants | 1 | 2004 | 408 | 0.190 |
Why?
|
| Enkephalins | 2 | 1999 | 16 | 0.190 |
Why?
|
| Kidney | 3 | 2015 | 1240 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 322 | 0.190 |
Why?
|
| Myocardial Contraction | 1 | 2001 | 244 | 0.190 |
Why?
|
| Gastric Mucosa | 1 | 2000 | 66 | 0.190 |
Why?
|
| North America | 2 | 2011 | 180 | 0.180 |
Why?
|
| Amphibian Venoms | 1 | 2000 | 1 | 0.180 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2000 | 50 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 645 | 0.180 |
Why?
|
| HT29 Cells | 2 | 2009 | 49 | 0.180 |
Why?
|
| Calibration | 2 | 2014 | 99 | 0.180 |
Why?
|
| Analysis of Variance | 4 | 2004 | 911 | 0.180 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2000 | 201 | 0.180 |
Why?
|
| Perioperative Care | 1 | 2001 | 161 | 0.180 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 827 | 0.170 |
Why?
|
| Receptors, Opioid, delta | 1 | 1999 | 7 | 0.170 |
Why?
|
| Naloxone | 3 | 2009 | 59 | 0.170 |
Why?
|
| Receptors, Opioid, kappa | 1 | 1999 | 15 | 0.170 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 2706 | 0.170 |
Why?
|
| Polysaccharides | 3 | 2006 | 89 | 0.170 |
Why?
|
| Brain | 2 | 2001 | 2216 | 0.170 |
Why?
|
| Time Factors | 6 | 2009 | 5211 | 0.170 |
Why?
|
| Endothelins | 1 | 1999 | 35 | 0.170 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 1998 | 15 | 0.170 |
Why?
|
| GABA Modulators | 1 | 1998 | 9 | 0.170 |
Why?
|
| Thrombin | 1 | 1999 | 61 | 0.170 |
Why?
|
| Anti-HIV Agents | 1 | 2001 | 149 | 0.160 |
Why?
|
| Gene Regulatory Networks | 2 | 2013 | 296 | 0.160 |
Why?
|
| Ion Channel Gating | 1 | 2001 | 324 | 0.160 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 1998 | 83 | 0.160 |
Why?
|
| Injections, Intravenous | 4 | 2005 | 242 | 0.160 |
Why?
|
| GABA Agonists | 3 | 2004 | 20 | 0.160 |
Why?
|
| Caspase 3 | 2 | 2012 | 159 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 2 | 2010 | 1041 | 0.160 |
Why?
|
| Arousal | 1 | 1998 | 170 | 0.160 |
Why?
|
| Sheep | 4 | 2001 | 239 | 0.150 |
Why?
|
| Medicine, Traditional | 2 | 2016 | 8 | 0.150 |
Why?
|
| Rhizome | 2 | 2009 | 6 | 0.150 |
Why?
|
| Substance P | 1 | 1997 | 61 | 0.150 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 114 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 879 | 0.140 |
Why?
|
| Pyrrolidines | 1 | 1996 | 58 | 0.140 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2006 | 44 | 0.140 |
Why?
|
| Metabolomics | 1 | 2016 | 68 | 0.140 |
Why?
|
| Cell Line | 2 | 2016 | 2469 | 0.140 |
Why?
|
| Affect | 1 | 1998 | 386 | 0.140 |
Why?
|
| Molecular Conformation | 1 | 2016 | 96 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 1998 | 161 | 0.140 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2014 | 199 | 0.130 |
Why?
|
| Vacuoles | 2 | 2013 | 46 | 0.130 |
Why?
|
| Pyridines | 2 | 2013 | 310 | 0.130 |
Why?
|
| Molecular Docking Simulation | 2 | 2013 | 46 | 0.130 |
Why?
|
| Analgesics | 1 | 1996 | 119 | 0.130 |
Why?
|
| Insulin | 3 | 2008 | 1160 | 0.130 |
Why?
|
| Adolescent | 5 | 2016 | 8984 | 0.130 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 895 | 0.130 |
Why?
|
| Models, Molecular | 3 | 2012 | 1286 | 0.130 |
Why?
|
| Superoxides | 2 | 2007 | 73 | 0.130 |
Why?
|
| Blood Urea Nitrogen | 1 | 2015 | 34 | 0.130 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2009 | 88 | 0.130 |
Why?
|
| Oxonic Acid | 1 | 2014 | 8 | 0.130 |
Why?
|
| Xanthine Oxidase | 1 | 2014 | 26 | 0.120 |
Why?
|
| Discriminant Analysis | 1 | 2014 | 66 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2015 | 7998 | 0.120 |
Why?
|
| Enteritis | 1 | 2014 | 21 | 0.120 |
Why?
|
| Malondialdehyde | 1 | 2014 | 27 | 0.120 |
Why?
|
| Glutathione Peroxidase | 1 | 2014 | 24 | 0.120 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 639 | 0.120 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 2007 | 306 | 0.120 |
Why?
|
| Feces | 1 | 2016 | 319 | 0.120 |
Why?
|
| Energy Metabolism | 2 | 2009 | 271 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 689 | 0.120 |
Why?
|
| Boraginaceae | 1 | 2013 | 3 | 0.120 |
Why?
|
| Naphthoquinones | 1 | 2013 | 5 | 0.120 |
Why?
|
| Ankle Joint | 1 | 2014 | 46 | 0.120 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 155 | 0.120 |
Why?
|
| Canada | 1 | 2014 | 204 | 0.120 |
Why?
|
| Oxidation-Reduction | 2 | 2006 | 373 | 0.120 |
Why?
|
| Prediabetic State | 1 | 2014 | 39 | 0.120 |
Why?
|
| Fluoresceins | 2 | 2004 | 43 | 0.120 |
Why?
|
| Reference Standards | 1 | 2014 | 159 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2013 | 86 | 0.120 |
Why?
|
| Isoflavones | 1 | 2013 | 13 | 0.120 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 100 | 0.120 |
Why?
|
| Iridoids | 1 | 2013 | 2 | 0.110 |
Why?
|
| Glucose Intolerance | 1 | 2014 | 96 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 311 | 0.110 |
Why?
|
| S Phase Cell Cycle Checkpoints | 1 | 2013 | 3 | 0.110 |
Why?
|
| Salvia miltiorrhiza | 1 | 2013 | 3 | 0.110 |
Why?
|
| Cyclin B1 | 1 | 2013 | 17 | 0.110 |
Why?
|
| Organ Size | 1 | 2014 | 363 | 0.110 |
Why?
|
| Acupuncture Therapy | 2 | 2004 | 11 | 0.110 |
Why?
|
| Hydrogen | 3 | 1998 | 47 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 391 | 0.110 |
Why?
|
| Thymus Gland | 1 | 2014 | 195 | 0.110 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2013 | 54 | 0.110 |
Why?
|
| Action Potentials | 4 | 2001 | 573 | 0.110 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2013 | 26 | 0.110 |
Why?
|
| Acupuncture Points | 2 | 2003 | 2 | 0.110 |
Why?
|
| Superoxide Dismutase | 1 | 2014 | 177 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 189 | 0.110 |
Why?
|
| Membrane Proteins | 2 | 2014 | 1196 | 0.110 |
Why?
|
| Spleen | 1 | 2014 | 430 | 0.110 |
Why?
|
| Knee Joint | 1 | 2014 | 168 | 0.110 |
Why?
|
| Tea | 1 | 2012 | 19 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 172 | 0.110 |
Why?
|
| United States | 3 | 2014 | 6681 | 0.110 |
Why?
|
| Body Temperature | 2 | 2004 | 124 | 0.110 |
Why?
|
| Fasting | 2 | 2004 | 161 | 0.110 |
Why?
|
| Species Specificity | 1 | 2014 | 678 | 0.110 |
Why?
|
| Annexin A5 | 1 | 2012 | 20 | 0.110 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 90 | 0.110 |
Why?
|
| HIV Infections | 1 | 2001 | 772 | 0.110 |
Why?
|
| Caspase 9 | 1 | 2012 | 48 | 0.110 |
Why?
|
| Enzyme Induction | 1 | 2012 | 88 | 0.110 |
Why?
|
| Microdialysis | 1 | 2012 | 32 | 0.100 |
Why?
|
| Biotransformation | 1 | 2011 | 50 | 0.100 |
Why?
|
| Hydrogen Bonding | 1 | 2012 | 144 | 0.100 |
Why?
|
| Catalytic Domain | 1 | 2012 | 156 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 1991 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1001 | 0.100 |
Why?
|
| Forecasting | 2 | 2003 | 305 | 0.100 |
Why?
|
| Enzyme Activation | 3 | 2014 | 692 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2011 | 113 | 0.100 |
Why?
|
| Microscopy, Video | 2 | 2002 | 34 | 0.100 |
Why?
|
| Dietary Fats | 1 | 2011 | 135 | 0.100 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 83 | 0.100 |
Why?
|
| Plant Bark | 1 | 2010 | 5 | 0.100 |
Why?
|
| Middle Aged | 6 | 2016 | 25035 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2011 | 295 | 0.090 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 93 | 0.090 |
Why?
|
| Glucuronates | 1 | 2010 | 22 | 0.090 |
Why?
|
| Apigenin | 1 | 2010 | 7 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2011 | 506 | 0.090 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2009 | 24 | 0.090 |
Why?
|
| Growth Inhibitors | 1 | 2009 | 41 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 315 | 0.090 |
Why?
|
| Binding Sites | 1 | 2012 | 1098 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 427 | 0.090 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2009 | 57 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 376 | 0.080 |
Why?
|
| Heating | 1 | 2008 | 14 | 0.080 |
Why?
|
| Kinetics | 2 | 2002 | 1513 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 536 | 0.080 |
Why?
|
| Liver | 1 | 2014 | 1228 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2000 | 308 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2011 | 485 | 0.080 |
Why?
|
| Intestines | 1 | 2012 | 411 | 0.080 |
Why?
|
| Cyclins | 1 | 2008 | 82 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 568 | 0.080 |
Why?
|
| Pain Measurement | 2 | 2003 | 321 | 0.080 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 2 | 1999 | 3 | 0.080 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 2 | 1999 | 10 | 0.080 |
Why?
|
| Cell Membrane | 2 | 2003 | 666 | 0.080 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 2 | 1999 | 22 | 0.080 |
Why?
|
| Protein Binding | 1 | 2012 | 1457 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1686 | 0.080 |
Why?
|
| Ethanol | 1 | 2010 | 249 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1195 | 0.080 |
Why?
|
| Acetylcysteine | 2 | 2010 | 69 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2005 | 1169 | 0.080 |
Why?
|
| Picrates | 1 | 2007 | 12 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2012 | 1078 | 0.080 |
Why?
|
| Hydroxyl Radical | 1 | 2007 | 35 | 0.080 |
Why?
|
| Hydrazines | 1 | 2007 | 30 | 0.070 |
Why?
|
| CD56 Antigen | 1 | 2007 | 18 | 0.070 |
Why?
|
| Camellia sinensis | 1 | 2007 | 6 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2000 | 840 | 0.070 |
Why?
|
| Thirst | 1 | 2007 | 19 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2008 | 369 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 1047 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1802 | 0.070 |
Why?
|
| Biphenyl Compounds | 1 | 2007 | 68 | 0.070 |
Why?
|
| Chlorogenic Acid | 1 | 2006 | 3 | 0.070 |
Why?
|
| Caffeic Acids | 1 | 2006 | 5 | 0.070 |
Why?
|
| Burns | 1 | 2008 | 131 | 0.070 |
Why?
|
| Fluorescent Dyes | 2 | 2006 | 242 | 0.070 |
Why?
|
| Catalase | 1 | 2006 | 48 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2012 | 763 | 0.070 |
Why?
|
| Cell Shape | 1 | 2006 | 51 | 0.070 |
Why?
|
| Uncoupling Agents | 1 | 2006 | 15 | 0.070 |
Why?
|
| Thymidine | 1 | 2006 | 59 | 0.070 |
Why?
|
| Reference Values | 2 | 1998 | 674 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1921 | 0.070 |
Why?
|
| Heart Ventricles | 2 | 2003 | 760 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 2262 | 0.070 |
Why?
|
| Fatigue | 1 | 2007 | 174 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2006 | 224 | 0.070 |
Why?
|
| Zingiberaceae | 2 | 2016 | 9 | 0.070 |
Why?
|
| Zanthoxylum | 2 | 2016 | 9 | 0.070 |
Why?
|
| Half-Life | 1 | 2005 | 96 | 0.070 |
Why?
|
| DNA Replication | 1 | 2006 | 164 | 0.070 |
Why?
|
| Antidiarrheals | 1 | 2005 | 14 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2006 | 420 | 0.070 |
Why?
|
| Quality of Life | 1 | 2013 | 1585 | 0.060 |
Why?
|
| Models, Animal | 1 | 2006 | 263 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 2 | 2009 | 125 | 0.060 |
Why?
|
| Ondansetron | 1 | 2004 | 21 | 0.060 |
Why?
|
| International Normalized Ratio | 1 | 2004 | 38 | 0.060 |
Why?
|
| Bicuculline | 1 | 2004 | 18 | 0.060 |
Why?
|
| Biofeedback, Psychology | 1 | 2004 | 12 | 0.060 |
Why?
|
| Young Adult | 1 | 2016 | 5980 | 0.060 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2004 | 22 | 0.060 |
Why?
|
| Microelectrodes | 1 | 2004 | 81 | 0.060 |
Why?
|
| Nerve Fibers | 1 | 2004 | 46 | 0.060 |
Why?
|
| Cats | 1 | 2004 | 304 | 0.060 |
Why?
|
| Chickens | 1 | 2004 | 212 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 399 | 0.060 |
Why?
|
| Iron | 1 | 2004 | 164 | 0.060 |
Why?
|
| Axons | 1 | 2004 | 174 | 0.060 |
Why?
|
| Cell Size | 1 | 2003 | 65 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 68 | 0.060 |
Why?
|
| Evoked Potentials | 1 | 2004 | 190 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 307 | 0.050 |
Why?
|
| Glucose Clamp Technique | 1 | 2002 | 39 | 0.050 |
Why?
|
| Asteraceae | 1 | 2002 | 4 | 0.050 |
Why?
|
| Hydrotherapy | 1 | 2002 | 5 | 0.050 |
Why?
|
| Myocardial Reperfusion | 1 | 2002 | 27 | 0.050 |
Why?
|
| Hyperphagia | 1 | 2002 | 35 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2003 | 270 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2005 | 429 | 0.050 |
Why?
|
| Neural Pathways | 1 | 2004 | 308 | 0.050 |
Why?
|
| Gastrointestinal Tract | 1 | 2004 | 191 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2002 | 117 | 0.050 |
Why?
|
| Garlic | 1 | 2001 | 1 | 0.050 |
Why?
|
| Echinacea | 1 | 2001 | 2 | 0.050 |
Why?
|
| Hypericum | 1 | 2001 | 2 | 0.050 |
Why?
|
| DNA | 1 | 2007 | 1294 | 0.050 |
Why?
|
| Ginkgo biloba | 1 | 2001 | 5 | 0.050 |
Why?
|
| Dogs | 2 | 2000 | 686 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 449 | 0.050 |
Why?
|
| Wisconsin | 1 | 2001 | 39 | 0.050 |
Why?
|
| Perfusion | 1 | 2002 | 203 | 0.050 |
Why?
|
| Atropine | 1 | 2001 | 59 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 425 | 0.050 |
Why?
|
| Ethnopharmacology | 1 | 2001 | 2 | 0.050 |
Why?
|
| Electron Transport | 1 | 2001 | 71 | 0.050 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2000 | 1 | 0.050 |
Why?
|
| Electric Conductivity | 1 | 2001 | 144 | 0.050 |
Why?
|
| Potassium Channels | 1 | 2003 | 340 | 0.050 |
Why?
|
| Lidocaine | 1 | 2001 | 63 | 0.050 |
Why?
|
| Body Weight Changes | 1 | 2000 | 1 | 0.050 |
Why?
|
| Diet | 1 | 2004 | 443 | 0.050 |
Why?
|
| Myocardial Ischemia | 1 | 2002 | 162 | 0.050 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2000 | 6 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2003 | 377 | 0.050 |
Why?
|
| Drug Design | 1 | 2001 | 124 | 0.050 |
Why?
|
| Phenethylamines | 1 | 2000 | 6 | 0.050 |
Why?
|
| Potassium | 1 | 2001 | 281 | 0.050 |
Why?
|
| Sodium Channels | 1 | 2001 | 129 | 0.050 |
Why?
|
| Lactulose | 1 | 2000 | 20 | 0.050 |
Why?
|
| Phytosterols | 1 | 1999 | 6 | 0.050 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2000 | 48 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 1 | 2001 | 396 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2012 | 615 | 0.040 |
Why?
|
| Illinois | 1 | 2001 | 462 | 0.040 |
Why?
|
| Sodium | 1 | 2001 | 341 | 0.040 |
Why?
|
| Nitroarginine | 1 | 1999 | 16 | 0.040 |
Why?
|
| Transfection | 1 | 2001 | 896 | 0.040 |
Why?
|
| Umbilical Cord | 1 | 1999 | 40 | 0.040 |
Why?
|
| Vagotomy | 1 | 1998 | 12 | 0.040 |
Why?
|
| Muscle, Smooth | 2 | 1998 | 354 | 0.040 |
Why?
|
| Chromatography, Gas | 1 | 1998 | 28 | 0.040 |
Why?
|
| Guinea Pigs | 2 | 1997 | 171 | 0.040 |
Why?
|
| Receptors, GABA-B | 1 | 1998 | 7 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 1999 | 167 | 0.040 |
Why?
|
| Receptors, GABA-A | 1 | 1998 | 32 | 0.040 |
Why?
|
| Hirschsprung Disease | 1 | 1998 | 11 | 0.040 |
Why?
|
| Piperidines | 1 | 2000 | 181 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2010 | 782 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 2000 | 161 | 0.040 |
Why?
|
| Cecum | 1 | 1998 | 68 | 0.040 |
Why?
|
| Muscle Contraction | 2 | 1998 | 284 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2000 | 300 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 429 | 0.040 |
Why?
|
| Histamine | 1 | 1997 | 126 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 1997 | 153 | 0.040 |
Why?
|
| Pressure | 1 | 1996 | 165 | 0.030 |
Why?
|
| Aging | 1 | 1999 | 691 | 0.030 |
Why?
|
| Ubiquitinated Proteins | 1 | 2014 | 4 | 0.030 |
Why?
|
| Ileum | 1 | 1995 | 159 | 0.030 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2014 | 22 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2014 | 74 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2014 | 35 | 0.030 |
Why?
|
| Jejunum | 1 | 2014 | 79 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2014 | 135 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 236 | 0.030 |
Why?
|
| Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2012 | 5 | 0.030 |
Why?
|
| Intestine, Small | 1 | 1995 | 302 | 0.030 |
Why?
|
| Life Style | 1 | 2014 | 189 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 188 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2012 | 72 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 154 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 229 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2012 | 67 | 0.030 |
Why?
|
| Autophagy | 1 | 2014 | 149 | 0.030 |
Why?
|
| Unfolded Protein Response | 1 | 2012 | 39 | 0.030 |
Why?
|
| Calcium | 1 | 1997 | 1156 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2012 | 170 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 179 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 286 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2012 | 154 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 2011 | 63 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 253 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 179 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 363 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2010 | 25 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2010 | 33 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 53 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 547 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 683 | 0.020 |
Why?
|
| Grape Seed Extract | 1 | 2009 | 4 | 0.020 |
Why?
|
| Protective Agents | 1 | 2009 | 33 | 0.020 |
Why?
|
| Peptides | 1 | 2012 | 639 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1532 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 1106 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 102 | 0.020 |
Why?
|
| Bacteria | 1 | 2011 | 447 | 0.020 |
Why?
|
| Aged | 2 | 2014 | 18421 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1208 | 0.020 |
Why?
|
| Critical Illness | 1 | 2008 | 294 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2012 | 1565 | 0.020 |
Why?
|
| Models, Biological | 1 | 2009 | 1749 | 0.010 |
Why?
|
| Mutation | 1 | 2010 | 3968 | 0.010 |
Why?
|
| Myenteric Plexus | 1 | 1998 | 1 | 0.010 |
Why?
|
| Rats, Mutant Strains | 1 | 1998 | 23 | 0.010 |
Why?
|
| Somatostatin | 1 | 1998 | 55 | 0.010 |
Why?
|
| Breeding | 1 | 1998 | 39 | 0.010 |
Why?
|
| Emetics | 1 | 1998 | 4 | 0.010 |
Why?
|
| Apomorphine | 1 | 1998 | 10 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1998 | 303 | 0.010 |
Why?
|
| Fura-2 | 1 | 1997 | 22 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1997 | 63 | 0.010 |
Why?
|
| Pedigree | 1 | 1998 | 966 | 0.010 |
Why?
|
| Radiography | 1 | 1998 | 811 | 0.010 |
Why?
|
| Biomarkers | 1 | 1998 | 1718 | 0.010 |
Why?
|